Hinrich Abken

13.0k total citations · 1 hit paper
219 papers, 10.2k citations indexed

About

Hinrich Abken is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Hinrich Abken has authored 219 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Oncology, 135 papers in Immunology and 65 papers in Molecular Biology. Recurrent topics in Hinrich Abken's work include CAR-T cell therapy research (156 papers), Immune Cell Function and Interaction (83 papers) and Immunotherapy and Immune Responses (57 papers). Hinrich Abken is often cited by papers focused on CAR-T cell therapy research (156 papers), Immune Cell Function and Interaction (83 papers) and Immunotherapy and Immune Responses (57 papers). Hinrich Abken collaborates with scholars based in Germany, United States and United Kingdom. Hinrich Abken's co-authors include Andreas Hombach, Markus Chmielewski, Gunter Rappl, Claudia Heuser, Barbara Seliger, Astrid Holzinger, Christoph Pohl, David E. Gilham, Uwe Reinhold and Christoph Heuser and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Hinrich Abken

216 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TRUCKs: the fourth generation of CARs

2015 563 citations Markus Chmielewski, Hinrich Abken profile →

Peers

Countries citing papers authored by Hinrich Abken

Since Specialization

Citations

This map shows the geographic impact of Hinrich Abken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hinrich Abken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hinrich Abken more than expected).

Fields of papers citing papers by Hinrich Abken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hinrich Abken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hinrich Abken. The network helps show where Hinrich Abken may publish in the future.

Co-authorship network of co-authors of Hinrich Abken

This figure shows the co-authorship network connecting the top 25 collaborators of Hinrich Abken. A scholar is included among the top collaborators of Hinrich Abken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hinrich Abken. Hinrich Abken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of antigen multimers for detection and evaluation of CAR T cells 2025 ·Cancer Immunology Immunotherapy ·(unknown), Maria Ormhøj, (unknown), (unknown), (unknown), Markus Barden, (unknown), (unknown), Morten Hartvig Hansen, Hinrich Abken, Sine Reker Hadrup	0
2	CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma 2023 ·Frontiers in Immunology ·(unknown), (unknown), Andrea Quaiser, (unknown), Hinrich Abken, Sandy Tretbar, Stephan Fricke, Ulrike Koehl, Dominik Schmiedel, Thomas Grünwald	17
3	CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation 2023 ·Frontiers in Immunology ·Markus Barden, Astrid Holzinger, (unknown), (unknown), Árpád Szöőr, György Vereb, Gerhard J. Schütz, Andreas Hombach, Hinrich Abken	14
4	CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop 2022 ·Cells ·Dennis Christoph Harrer, (unknown), (unknown), (unknown), Jordan Hartley, Markus Barden, Hong Pan, Astrid Holzinger, Wolfgang Herr, Hinrich Abken	9
5	IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors 2021 ·Molecular Therapy ·Andreas Hombach, Markus Barden, (unknown), Markus Chmielewski, Gunter Rappl, Agapios Sachinidis, Hinrich Abken	38
6	Cyclooxygenases Inhibitors Efficiently Induce Cardiomyogenesis in Human Pluripotent Stem Cells 2020 ·Cells ·Harshal Nemade, (unknown), Umesh Chaudhari, (unknown), Filomain Nguemo, (unknown), Hinrich Abken, Jürgen Hescheler, Symeon Papadopoulos, Agapios Sachinidis	9
7	Using Antigen-Specific B Cells to Combine Antibody and T Cell–Based Cancer Immunotherapy 2017 ·Cancer Immunology Research ·Kerstin Wennhold, Martin Thelen, Hans Schlößer, (unknown), (unknown), María A. García-Márquez, Axel Lechner, Sebastian Kobold, Felicitas Rataj, Olaf Utermöhlen, Geothy Chakupurakal, Sebastian Theurich, Michael Hallek, Hinrich Abken, Alexander Shimabukuro‐Vornhagen, Michael von Bergwelt‐Baildon	28
8	Release brakes: chimeric antigen receptor T cells with PD-1 switch receptor 2016 ·Translational Cancer Research ·Markus Chmielewski, Hinrich Abken	1
9	Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFNγ 2014 ·Cancer Research ·Ana Textor, (unknown), (unknown), Cynthia Pérez, Anna Kruschinski, Markus Chmielewski, Hinrich Abken, Thomas Blankenstein, Jehad Charo	58
10	Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice 2012 ·Gastroenterology ·(unknown), Charlotte Servais, Tova Waks, Markus Chmielewski, Ron Lavy, Peter Altevogt, Hinrich Abken, Zelig Eshhar	86
11	Eradication of melanomas by targeted elimination of a minor subset of tumor cells 2011 ·Proceedings of the National Academy of Sciences ·Patrick Schmidt, (unknown), Andreas Hombach, Paola Zigrino, Cornelia Mauch, Hinrich Abken	87
12	The Proteasome Inhibitor Bortezomib Sensitizes Melanoma Cells toward Adoptive CTL Attack 2010 ·Cancer Research ·Jens M. Seeger, Patrick Schmidt, Kerstin Brinkmann, Andreas Hombach, Oliver Coutelle, Paola Zigrino, (unknown), Cornelia Mauch, Hinrich Abken, Martin Krönke, Hamid Kashkar	47
13	Rational development of high-affinity T-cell receptor-like antibodies 2009 ·Proceedings of the National Academy of Sciences ·Guillaume Stewart-Jones, Andreas Wadle, (unknown), Eugene Shenderov, Gerhard Held, Eliane Fischer, Sascha Kleber, Natko Nuber, Frank Stenner, Stefan Bauer, Andrew McMichael, Alexander Knuth, Hinrich Abken, Andreas Hombach, Vincenzo Cerundolo, E. Yvonne Jones, Christoph Renner	90
14	T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes 2008 ·Gastroenterology ·Felix Bohne, Markus Chmielewski, Gregor Ebert, Katja Wiegmann, (unknown), Andreas Schulze, Stephan Urban, Martin Krönke, Hinrich Abken, Ulrike Protzer	135
15	Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas 2008 ·Proceedings of the National Academy of Sciences ·Anna Kruschinski, Andreas Moosmann, Isabel Poschke, Håkan Norell, Markus Chmielewski, Barbara Seliger, Rolf Kiessling, Thomas Blankenstein, Hinrich Abken, Jehad Charo	158
16	Effective Proliferation of Human Regulatory T Cells Requires a Strong Costimulatory CD28 Signal That Cannot Be Substituted by IL-2 2007 ·The Journal of Immunology ·Andreas Hombach, David M. Kofler, (unknown), Gunter Rappl, Hinrich Abken	41
17	Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated into One Combined CD28/CD3ζ Signaling Receptor Molecule 2004 ·The Journal of Immunology ·Andreas Hombach, (unknown), Thomas P. Marquardt, Claudia Heuser, (unknown), (unknown), Barbara Seliger, Hinrich Abken	1
18	T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. 2001 ·PubMed ·Andreas Hombach, (unknown), Christophe Schneider, Claudia Heuser, (unknown), Christoph Pohl, Barbara Seliger, Hinrich Abken	96
19	Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule 2001 ·The Journal of Immunology ·Andreas Hombach, (unknown), (unknown), Claudia Heuser, (unknown), Christoph Pohl, Barbara Seliger, Hinrich Abken	251
20	CD4+ T Cells Engrafted with a Recombinant Immunoreceptor Efficiently Lyse Target Cells in a MHC Antigen- and Fas-Independent Fashion 2001 ·The Journal of Immunology ·Andreas Hombach, Claudia Heuser, (unknown), (unknown), (unknown), Christoph Pohl, Hinrich Abken	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact